Moleculin Biotech Inc. has announced the launch of its CEO Corner platform, designed to provide enhanced insight into the company’s corporate developments, clinical progress, and strategic initiatives. The company plans to use this platform to deliver deeper context on its pipeline programs, clinical milestones, and business strategy. Moleculin is focused on advancing its lead program, Annamycin, which is in development for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. Additional pipeline development includes WP1066, targeting brain tumors and other cancers, and WP1122, being explored for the treatment of pathogenic viruses and certain cancer indications. The company aims to deliver long-term value for shareholders and encourages stakeholders to submit questions and topics for future updates through the CEO Corner.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9654234-en) on February 13, 2026, and is solely responsible for the information contained therein.